La Reunión Anual de la American Society of Clinical Oncology (Sociedad Estadounidense de Oncología Clínica) de 2022 se llevará a cabo del 3 al 7 de junio. En esta publicación inicial de la investigación que se presenta en la reunión, los estudios examinan cómo la raza, el origen étnico, la pobreza y otros factores sociales y demográficos afectan la vida de las personas con cáncer.

The 2022 ASCO Annual Meeting is being held June 3 to 7. In this early release of research being presented at the meeting, studies examine how race, ethnicity, poverty, and other social and demographic factors affect the lives of people with cancer.

In this month’s “From the Editor in Chief” column, Dr. Jyoti Patel discusses the disparities that exist in cancer clinical trials and how cancer care providers are working to address the barriers to participation in clinical trials for minority populations.

Patient advocate Patty Spears discusses what eligibility criteria for cancer clinical trials are, why they’re important to cancer research, and how eligibility criteria are changing to include more people with cancer in clinical trials.

The ASCO Annual Meeting begins on June 4, and here is some of the notable research that will be presented. Topics include combined immunotherapy for esophageal cancer, targeted radiation for mCRPC, olaparib for HER2-negative breast cancer, adjuvant chemotherapy for cervical cancer, pembrolizumab for kidney cancer, and toripalimab for nasopharyngeal cancer.

As the 2021 ASCO Annual Meeting approaches, learn why the meeting is important for people diagnosed with cancer, how research from the meeting can change cancer care, and how to register in advance.

In the latest podcast in the “Clinical Trials in Genitourinary Cancers” series, experts discuss 3 clinical trials testing new treatment options for kidney cancer, muscle-invasive bladder cancer, and metastatic castration-sensitive prostate cancer.

Read early research highlights just released for the 2021 ASCO Annual Meeting. Topics include immunotherapy for melanoma and non-small cell lung cancer, PSA screening for prostate cancer, HPV vaccination, and Medicaid income eligibility limits.

Lea los puntos destacados de la investigación temprana que acaban de publicar para la reunión anual de la American Society of Clinical Oncology (Sociedad Americana de Oncología Clínica) de 2021. Los temas incluyen la inmunoterapia para el melanoma y el cáncer de pulmón de no microcítico (NSCLC, por sus siglas en inglés), la detección del antígeno prostático específico (PSA, por sus siglas en inglés) para el cáncer de próstata, la vacunación contra el VPH y los límites de elegibilidad de los ingresos de Medicaid.

In this month’s “From the Editor’s Desk,” Dr. Lidia Schapira reflects on the importance of the National Cancer Act of 1971 for people with cancer and how the Act still plays a critical role in cancer research today, 50 years later.